| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 48 Number 6
Volume 48 Number 5
Volume 48 Number 4
Volume 48 Number 3
Volume 48 Number 2
Volume 48S Number 1
Earlier issues
Volume 47 Number 6 Volume 48 Number 1

previous article next article

Research articles

ScienceAsia 48 (2022): 8-14 |doi: 10.2306/scienceasia1513-1874.2022.003

Fibrinogen with high-sensitivity C-reactive protein: A combined prediction biomarker for acute coronary syndrome risk assessment

Chananikan Makmoola,b, Burabha Pussadhammab,c, Wit Leuangwatthananond, Songpol Howhanb,e, Nantarat Komanasinb,e,*

ABSTRACT:     Increased level of either fibrinogen or high-sensitivity C-reactive protein (hs-CRP) is associated with outcomes of cardiovascular disease. This study aimed to investigate whether combining these two parameters could provide an improved prognostic biomarker for subjects with acute coronary syndrome (ACS). A total of 51 ACS subjects and 52 control individuals (having atypical chest pain without significant coronary stenosis) were retrospectively enrolled in this study. Fibrinogen and hs-CRP concentrations were determined using automated analyzers. Receiver operating characteristic (ROC) curves were constructed to assess the prognostic power of single and combined biomarkers. Regression analysis was performed to investigate the association of the biomarkers with ACS risk. The combined biomarkers exhibited an improved area under the ROC curve, which was higher than that of the individual biomarkers alone. Logistic regression analysis indicated that the ACS risk among subjects with concurrent elevated levels of fibrinogen and hs-CRP [adjusted OR (95% CI) = 11.6 (3.8, 35.2)] was approximately two-fold higher than that of those with single elevated parameter. In conclusion, high fibrinogen and hs-CRP levels can be utilized in combination as an enhanced prediction biomarker for clinical risk assessment of ACS in patients with coronary artery disease.

Download PDF

78 Downloads 464 Views

a Biomedical Sciences Program, Graduate School, Khon Kaen University, Khon Kaen 40002 Thailand
b Cardiovascular Research Group, Khon Kaen University, Khon Kaen 40002 Thailand
c Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002 Thailand
d Queen Sirikit Heart Center of the Northeast, Khon Kaen University, Khon Kaen 4002 Thailand
e School of Medical Technology, Faculty of Associated Medical Sciences, Khon Kaen 4002 Thailand

* Corresponding author, E-mail: nankom@kku.ac.th

Received 26 Mar 2021, Accepted 13 Jul 2021